Updates on Preprocedural Evaluation and Patient Selection for Prostatic Artery Embolization.

Benign prostatic hyperplasia remains a common condition affecting older men. Established knowledge includes the use of medications and surgery to manage symptoms. However, gaps persist in understanding optimal patient selection for newer treatments. Prostatic artery embolization has emerged as a promising alternative. Prior research has shown PAE to be a safe and effective treatment. Yet, the specific criteria for patient evaluation remain unclear. This uncertainty drives the need for updated guidelines. No prior work has resolved the best combination of clinical and imaging assessments.

This review aims to clarify the preprocedural evaluation process for PAE. It focuses on identifying the most relevant clinical and imaging criteria. The motivation stems from the growing adoption of PAE in clinical practice. Authors propose that standardized evaluation improves patient outcomes. They suggest that symptom scoring and objective testing are essential. The study also considers the role of advanced imaging techniques. This work addresses the need for updated patient selection strategies. It emphasizes the importance of evidence-based evaluation methods.

The authors conducted a literature review to synthesize current evidence. They analyzed clinical guidelines and recent studies on PAE. The review included symptom scoring systems like the IPSS and IIEF. Objective tests such as PSA and uroflowmetry were evaluated. Imaging modalities like CTA and MRA were discussed. The authors also considered urodynamic studies in select cases. They examined how imaging can reveal prostate morphology and vasculature. This approach allowed them to propose updated evaluation protocols.

The strongest finding is the importance of symptom scoring in patient evaluation. The IPSS and IIEF scores help assess urinary and erectile function. PSA levels and postvoid residual volume are key objective measures. Uroflowmetry provides functional data on urinary flow. CTA and MRA offer detailed imaging of prostate vasculature. These imaging techniques also detect prostate cancer. Urodynamic studies are reserved for specific patient cases. The authors suggest these findings guide patient selection for PAE.

The authors propose that a comprehensive evaluation is necessary for PAE. They suggest combining symptom scores with objective tests like PSA and uroflowmetry. Imaging with CTA or MRA is recommended to assess prostate morphology. These findings may improve patient selection and procedural outcomes. The authors also suggest that urodynamic studies are useful in select cases. Their synthesis highlights the need for standardized evaluation protocols. This work may guide clinicians in adopting PAE safely and effectively. It emphasizes the role of updated evidence in patient selection.